September 9, 2021 -- The U.S. Patent and Trademark Office has granted ONK Therapeutics patents covering the company's cytokine-inducible SH2-containing (CISH) knockout in NK cells, irrespective of the source of the NK cells.
The patents cover human cord blood-derived and human-induced pluripotent stem cell-derived cells.
Earlier this year, ONK entered an exclusive global patent license agreement with Australia's Walter and Eliza Hall Institute of Medical Research (WEHI) that provides ONK rights to CISH knockout in the field of human NK cells for the treatment of cancer, with the right to sublicense.
CIS is a protein encoded by CISH. In 2015, WEHI researchers demonstrated the role CIS plays in regulating the function of NK cells.If you like this content, please share it with a colleague!
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
